ACET Stock Analysis: Buy, Sell, or Hold?
ACET - Adicet Bio, Inc. Common Stock
$8.55
0.23 (2.76%)
▲
5d:
+4.27%
30d:
+24.64%
90d:
+21.62%
BUY
MODERATE Confidence
Analysis Updated: May 8, 2026 12:00 AM ET
Earnings: May 12, 2026
1d
Smart Money Distribution
ACET is up 20.9% this week, but smart money is buying puts. Top strike: $5 2026-05-15 with 1 OI. Put ratio: 100% View Scanner →
Strength: 10.0/10
Get Alerted When ACET Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ACET shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: ACET shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: ACET is currently trading at $8.55, which is considered extended relative to its 30-day fair value range of $6.95 to $8.39.
Technical Outlook: Technically, ACET is in a uptrend. Immediate support is located at $7.29, while resistance sits at $8.90.
Market Sentiment: ACET has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $34.83 (+307.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ACET is in a uptrend. Immediate support is located at $7.29, while resistance sits at $8.90.
Market Sentiment: ACET has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $34.83 (+307.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$6.95 -
$8.39
Company Quality Score
63/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
70.8%
All Signals
- BEARISH: Price extended above range
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 307.4% below Wall St target ($34.83)
Trading Range Analysis
30-Day Trading Range
$6.95 -
$8.39
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$1.07
(12.5%)
Support & Resistance Levels
Support Level
$7.29
Resistance Level
$8.90
Current Trend
Uptrend
Technical data as of
May 8, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.10
Wall Street Target
$34.83
(+307.4%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: May 10, 2026 1:09 PM ET
Data refreshes hourly during market hours. Next update: 2:09 PM
Data refreshes hourly during market hours. Next update: 2:09 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ACET showing a specific setup today?
Insider Activity (6 Months)
3
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Ra Capital Management, L…
BUY
74751 shares
2026-02-20
Ra Capital Management, L…
BUY
74268 shares
2026-02-19
Ra Capital Management, L…
BUY
74577 shares
2026-02-18
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$550 | 60 BUY |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$57 | 54 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$53 | 60 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$875 | 52 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$79 | 57 HOLD |
